id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2046-0009,FDA,FDA-2020-E-2046,Certificate Extending Patent Term,Other,Certificate Extending Patent Term,2024-07-31T04:00:00Z,2024,7,2024-07-31T04:00:00Z,,2024-07-31T12:18:36Z,,0,0,0900006486605f0a
FDA-2020-E-2046-0008,FDA,FDA-2020-E-2046,Notice of Final Determination,Other,Letter(s),2024-04-10T04:00:00Z,2024,4,2024-04-10T04:00:00Z,,2024-04-10T16:13:53Z,,0,0,09000064864c165d
FDA-2020-E-2046-0007,FDA,FDA-2020-E-2046,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2023-07-13T04:00:00Z,2023,7,2023-07-13T04:00:00Z,,2024-04-08T20:02:39Z,,0,0,0900006485ca2482
FDA-2020-E-2046-0005,FDA,FDA-2020-E-2046,Determination of Regulatory Review Period for Purposes of Patent Extension; NEXLETOL,Notice,Determinations,2022-11-09T05:00:00Z,2022,11,2022-11-09T05:00:00Z,2023-01-10T04:59:59Z,2022-11-10T02:00:26Z,2022-24431,0,0,090000648549d0f5
FDA-2020-E-2046-0004,FDA,FDA-2020-E-2046,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-09-08T04:00:00Z,2022,9,2022-09-08T04:00:00Z,,2022-09-08T16:16:29Z,,0,0,09000064852ce24c
FDA-2020-E-2046-0003,FDA,FDA-2020-E-2046,Letter to U S Patent and Trademark Office,Other,Letter(s),2020-12-14T05:00:00Z,2020,12,2020-12-14T05:00:00Z,,2020-12-14T15:34:06Z,,0,0,090000648499c79a
FDA-2020-E-2046-0002,FDA,FDA-2020-E-2046,Patent Term Extension Application for NEXLETOL,Other,Application,2020-10-02T04:00:00Z,2020,10,2020-10-02T04:00:00Z,,2020-10-02T21:47:15Z,,0,0,09000064848b8f84
FDA-2020-E-2046-0001,FDA,FDA-2020-E-2046,Letter from the U S Patent and Trademark Office to FDA CDER,Other,Application,2020-10-02T04:00:00Z,2020,10,2020-10-02T04:00:00Z,,2020-10-02T21:46:19Z,,0,0,09000064848b8f82